Washington University School of Medicine
St Louis, Missouri, 63144, United States
NCT Number: NCT03077620
The purpose of this study is to change the concentration of amyloid-beta in human cerebrospinal fluid (CSF) by modification of sleep efficiency.
Looking for future studies?
Notify Me45 year–65 year
All sexes
Interventional
Not applicable
St Louis, Missouri, 63144, United States
The purpose of the study is to investigate whether or not increasing sleep efficiency will change the concentration of amyloid-beta in cerebrospinal fluid (CSF).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will be given a sleep aid (10mg or 20mg suvorexant) at bedtime for two consecutive nights that they are spending in a research unit.
Other names: Belsomra
Participants will be given a placebo at bedtime for two consecutive nights that they are spending in a research unit.
Other names: sugar pill
Time frame: 36 hours of CSF collection
Mean difference in amyloid-beta-42 concentration between individuals with poor sleep efficiency (Poor sleep group control) compared to those with good sleep efficiency (Good sleep group)
Time frame: 36 hours of CSF collection
Mean difference in amyloid-beta-42 concentration between individuals with poor sleep efficiency who were treated with placebo (Poor sleep group control), Suvorexant 10 mg (Poor sleep group treatment 1), and Suvorexant 20 mg (Poor sleep group treatment 2)
Washington University School of Medicine
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02063217
Amyloid-beta, Pathological Conditions, Anatomical
St Louis, Missouri, United States
View Trial DetailsNCT06649760
Caries,Dental, Dental Caries
Alexandria, Egypt
View Trial DetailsNCT07640399
Bleeding, Gingival Diseases
Mississauga, Ontario, Canada
View Trial DetailsNCT04032626
Alzheimer Disease, Amyloid Plaque
Phoenix, Arizona, United States
View Trial Details